Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats. [PDF]
Khoshbakht E +4 more
europepmc +1 more source
Fibrocalculous Pancreatic Diabetes: Changing Clinical Spectrum and Glycaemic Response to Pioglitazone. [PDF]
David D +3 more
europepmc +1 more source
[<sup>18</sup>F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review. [PDF]
Gijsen CEW +4 more
europepmc +1 more source
Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy. [PDF]
Pfaller AT +26 more
europepmc +1 more source
Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea. [PDF]
Choi YY, Jeon J, Baik M, Yoo J, Kim J.
europepmc +1 more source
Association Between Thiazolidinedione Therapy and Tuberculosis-Related Events in Type 2 Diabetes: A Population-Based Cohort Study. [PDF]
Yen FS +7 more
europepmc +1 more source
The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists. [PDF]
Mahoon DA, Hamad O, Butler AE.
europepmc +1 more source
Differential Effects of Oral Antidiabetic Drugs on Skeletal Muscle Mass and Hemoglobin Levels in Adults with Type 2 Diabetes Mellitus: A Prospective Real-World Cohort Study. [PDF]
Ziyadanoğlu FP +5 more
europepmc +1 more source
Is there still room for pioglitazone in contemporary type 2 diabetes management? [PDF]
Caruso I.
europepmc +1 more source
The Metabolic-Inflammatory Axis in Hypertrophic Cardiomyopathy. [PDF]
Ermer KJ, Sequeira V.
europepmc +1 more source

